Sharemaestro company-news research for CervoMed Inc. (CRVO), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest CRVO news and sentiment
CervoMed Inc.
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
9 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone73/100
→
Published 30-day score51/100
Latest source headline
Roth MKM Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $7
Moomoo · 01 Oct 2026 20:25
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
9 current stories are mapped specifically to CRVO.
What limits the score
Only 1 publisher currently contribute to the measured read.
The stories agree, but freshness-weighted evidence is only 0.046.
Confidence is 18/100, below the threshold for a firm score.
51/100
News scoreEarly balanced news score
18/100
Confidencethin evidence
100%/100
Company news9 company stories
99/100
Story agreement1/100 difference
News history
Daily score and story count over 30 days
11 Sep26 Sep10 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence1
0.046 after freshness weightingSource breadth20
1 independent publishersCompany relevance100
share tied directly to this companyFreshness15
recency-weighted evidenceAgreement99
how closely stories agreePublisher mix0
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks16 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202651USD 3.22+6.6%
02 Oct 202654USD 3.02+18.9%
25 Sep 202650USD 2.54+4.5%
18 Sep 202650USD 2.43-5.4%
11 Sep 202650USD 2.57+0.4%
04 Sep 202652USD 2.56-1.5%
28 Aug 202654USD 2.6-0.8%
21 Aug 202655USD 2.62-4.0%
Provisional evidence
News subjects
What is shaping the score
Market update505 stories · 56%
Analyst action732 stories · 22%
Earnings502 stories · 22%
Source mix
Where the evidence comes from
Moomoo732 stories · 22%
Stock Titan502 stories · 22%
Yahoo! Finance Canada502 stories · 22%
Simply Wall Street501 stories · 11%
Investing.com Nigeria501 stories · 11%
The Manila Times501 stories · 11%
Recurring subjects
Subjects appearing most often
Life Sciences9Financial Markets4Finance4Earnings3
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
21 Jun50 neutral10 Oct 21:04
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 10 Oct 21:04 | 51 | -4 | 17/100 (-14) | 9 (-7) | Provisional |
| 01 Oct 23:59 | 55 | +2 | 31/100 (+1) | 16 (+2) | Provisional |
| 29 Sep 23:59 | 53 | +3 | 30/100 (+30) | 14 (+2) | Provisional |
| 28 Sep 23:59 | 50 | +0 | 0/100 (0) | 12 (+3) | Insufficient |
| 22 Sep 23:59 | 50 | -1 | 0/100 (-16) | 9 (-7) | Insufficient |
| 10 Sep 23:59 | 51 | +0 | 16/100 (0) | 16 (0) | Provisional |
| 09 Sep 23:59 | 51 | +0 | 16/100 (-1) | 16 (-2) | Provisional |
| 08 Sep 23:59 | 51 | +0 | 17/100 (0) | 18 (-2) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 9 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Analyst action2 stories
0.0%100.0%
Each side uses the same scale: 0–100.0% of the retained directional evidence.
Where the influence comes from
100.0%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
72/100 tone
Roth MKM has reiterated its Buy rating on CervoMed (CRVO.US) and maintained a target price of $7. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
63.4% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Roth MKM has reiterated its Buy rating on CervoMed (CRVO.US) and maintained a target price of $7. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
- Published
- 01 Oct 2026 20:25
- News subject
- Analyst action
- Why this score
- Buy Rating
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 52/100
- 30-day weight
- 63.4% of directional evidence · 9.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Hopeful Week For Insiders Who Bought US$3.46m Of CervoMed Stock
Insiders at CervoMed Inc. purchased US$3.46 million worth of shares over the last year, with Independent Chair Joshua Boger making the largest buy of US$3.0 million. Despite a recent 18% price gain, these insiders are still down US$448,000 on their investments, indicating an expensive wag…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Insiders at CervoMed Inc. purchased US$3.46 million worth of shares over the last year, with Independent Chair Joshua Boger making the largest buy of US$3.0 million. Despite a recent 18% price gain, these insiders are still down US$448,000 on their investments, indicating an expensive wager. The significant insider ownership of 26% and past buying activity suggest confidence in the company's future, even if current returns are negative.
- Published
- 01 Oct 2026 11:28
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
Market updateNot used in direction
CervoMed: FDA removes neflamapimod exposure limit | CRVO Stock News
CervoMed (CRVO) announced that the FDA has removed the prior drug-exposure limit for its neflamapimod treatment after a 39-week dog study established a high no-observed-adverse-effect level. This regulatory change, along with a new 50 mg oral tablet formulation designed for twice-daily do…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
CervoMed (CRVO) announced that the FDA has removed the prior drug-exposure limit for its neflamapimod treatment after a 39-week dog study established a high no-observed-adverse-effect level. This regulatory change, along with a new 50 mg oral tablet formulation designed for twice-daily dosing, provides greater flexibility for future clinical trials. The company plans to advance a 100 mg twice-daily regimen, expecting higher trough concentrations and lower peak concentrations, which are favorable for clinical activity and safety.
- Published
- 29 Sep 2026 07:04
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsLife Sciences
74/100 tone
JonesTrading has reiterated its Buy rating on CervoMed (CRVO.US) and maintained its target price at $12. This indicates a continued positive outlook from the firm regarding CervoMed's stock performance. Investors will likely view this as a sign of confidence in the company's future prospe…
36.6% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
JonesTrading has reiterated its Buy rating on CervoMed (CRVO.US) and maintained its target price at $12. This indicates a continued positive outlook from the firm regarding CervoMed's stock performance. Investors will likely view this as a sign of confidence in the company's future prospects.
- Published
- 29 Sep 2026 06:01
- News subject
- Analyst action
- Why this score
- Buy Rating
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 53/100
- 30-day weight
- 36.6% of directional evidence · 11.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
CervoMed advances higher-dose neflamapimod formulation By Investing.com
CervoMed Inc. announced the development of a new 50 mg tablet formulation of neflamapimod and plans for a 100 mg twice-daily dosing regimen in future clinical trials. This new formulation addresses manufacturing variability and offers a pharmacokinetic profile suitable for twice-daily adm…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
CervoMed Inc. announced the development of a new 50 mg tablet formulation of neflamapimod and plans for a 100 mg twice-daily dosing regimen in future clinical trials. This new formulation addresses manufacturing variability and offers a pharmacokinetic profile suitable for twice-daily administration. The company is now seeking a strategic partner to advance neflamapimod into a Phase 3 trial for dementia with Lewy bodies.
- Published
- 28 Sep 2026 21:28
- News subject
- Market update
- Why this score
- Strategic partnership
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Life Sciences
—Unscored
EarningsNot used in direction
CervoMed Inc. (CRVO) Stock Price, News, Quote & History
This article provides a comprehensive overview of CervoMed Inc. (CRVO), a clinical-stage biotechnology company. It details the company's stock performance, key financial metrics, and its development of neflamapimod for age-related neurologic disorders. The report also includes analyst rat…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides a comprehensive overview of CervoMed Inc. (CRVO), a clinical-stage biotechnology company. It details the company's stock performance, key financial metrics, and its development of neflamapimod for age-related neurologic disorders. The report also includes analyst ratings, earnings trends, and valuation measures for CRVO.
- Published
- 28 Sep 2026 12:00
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
—Unscored
CervoMed Inc. announced advancements for its lead drug candidate, neflamapimod, including a new 50 mg oral tablet formulation with an improved pharmacokinetic profile and the FDA's removal of a previous drug exposure limit. These developments enable CervoMed to pursue a higher-dose, 100 m…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
CervoMed Inc. announced advancements for its lead drug candidate, neflamapimod, including a new 50 mg oral tablet formulation with an improved pharmacokinetic profile and the FDA's removal of a previous drug exposure limit. These developments enable CervoMed to pursue a higher-dose, 100 mg twice-daily regimen in future clinical trials, aimed at achieving higher plasma trough drug concentrations associated with clinical activity. The company anticipates these changes will reduce clinical execution and manufacturing risks as they advance the neflamapimod program for age-related brain disorders.
- Published
- 28 Sep 2026 07:30
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
Life Sciences
—Unscored
Market updateNot used in direction
A neuroscience panel in New York will include CervoMed management Sept. 29
CervoMed (CRVO) will participate in the 5th Annual ROTH Healthcare Opportunities Conference in New York, NY, on September 29, 2026. Company management will join a panel discussion titled “Frontiers in Neuroscience” and hold one-on-one meetings with investors. A recording of the panel will…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
CervoMed (CRVO) will participate in the 5th Annual ROTH Healthcare Opportunities Conference in New York, NY, on September 29, 2026. Company management will join a panel discussion titled “Frontiers in Neuroscience” and hold one-on-one meetings with investors. A recording of the panel will be made available after the conference.
- Published
- 22 Sep 2026 20:20
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 18.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinanceLife Sciences
—Unscored
Market updateNot used in direction
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
CervoMed Inc. will participate in the 5th Annual ROTH Healthcare Opportunities Conference, with management speaking on a "Frontiers in Neuroscience" panel and holding one-on-one meetings on September 29, 2026. The clinical-stage company is focused on developing treatments for age-related …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
CervoMed Inc. will participate in the 5th Annual ROTH Healthcare Opportunities Conference, with management speaking on a "Frontiers in Neuroscience" panel and holding one-on-one meetings on September 29, 2026. The clinical-stage company is focused on developing treatments for age-related neurologic disorders, with lead candidate neflamapimod targeting neuroinflammation and neurodegeneration. CervoMed has completed a Phase 2b trial for neflamapimod in DLB and is progressing with Phase 2a trials for nfvPPA and EXPERTS-ALS.
- Published
- 22 Sep 2026 16:57
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 18.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 4 consolidated
FinanceLife Sciences
Earlier company news
CRVO news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 69 older CRVO headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to CRVO, but the headline and available text are not mainly about CervoMed Inc.. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of CRVO sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.